129Xe MRI scans
Preclinical
129Xe MRI scans is one of 10 therapeutic programs targeting Lung. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
9
Competitors
Pipeline
Status by Indication[2][1]
Competition
Competitive Landscape
9 competitors in Lung
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 2
Cyramza
Eli LillyPhase 2
Vepesid
AAvyxa
Phase 2
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 2
Paraplatin
AAvyxa
Phase 2
Adstiladrin
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 2
Taxotere
AAvyxa
Phase 2
Cytalux
OOn Target Laboratories, LLC
Phase 3
Luvometinib
SShanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 2
129Xe MRI scans
SSean Fain
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for 129Xe MRI scans. EMBL-EBI & Wellcome Sanger Institute.
- [3]